Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)

Aris Lacis; Inguna Lubaua; Valts Ozolins; Eriks Jekabsons; Andis Lacis; Mara Ratniece; Andrejs Erglis

doi:doi:10.11648/j.cmr.20130203.13

| Peer-Reviewed

Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)

Aris Lacis, Inguna Lubaua, Valts Ozolins, Eriks Jekabsons, Andis Lacis, Mara Ratniece, Andrejs Erglis

Published in Clinical Medicine Research (Volume 2, Issue 3)

Received: 28 April 2013 Published: 30 May 2013

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Pulmonary arterial hypertension (APAH, IPAH) is a devastating, progressive disease with increasingly debilitating symptoms [1,2].Intrapulmonary delivery of autologous stem cells could be beneficial for pathogenetic treatment for patients with severe pulmonary arterial hypertension.Two patients with severe pulmonary artery hypertension received intrapulmonary autologous mesenchymal (mononuclear) stem cell transplantation and stem cell transplantation in pulmonary arteries. Patients were examined by scintigraphy of lungs during the periods 12, 14 and 27 months after stem cell transplantation. We find out that perfusion in all lung segments were improved after 14 and 27 months.

Published in	Clinical Medicine Research (Volume 2, Issue 3)
DOI	10.11648/j.cmr.20130203.13
Page(s)	32-36
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2013. Published by Science Publishing Group

Keywords

Stem Cell Transplantation, Intrapulmonary Delivery, Pulmonary Artery Hypertension, Pulmonary Vascular Resistance

References

[1]	Rubin L. Primary pulmonary hypertension. N.Engl. J. Med., 1997; 336: 111-17.
[2]	Galie N., Rubin L., eds. Pulmonary arterial Hypertension. Epidemiology, pathology, assessment and therapy. J.Am.Coll.Cardiol., 2004; 43: 81-90.
[3]	Lammers A.F., Hislop A.A., Flynn Y. et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007; 93: 739-43.
[4]	Maiya S., Hislop A.A, Flynn Y., et al. Response to bosentan in children with pulmonary hypertension. Heart, 2006; 92:664-70.
[5]	Haworth S., Flynn Y., Hislop A.A. Survival and quality of life in children with severe pulmonary hypertension. Heart, 2006;92: (Suppl. II): A14.
[6]	Hislop A.A., Flynn Y., Haworth S.G. Summary of the experiences of the UK pulmonary hypertension service for children 2001 – 2005. Proceedings of the American Thoracic Society, 2006; 3: A57.
[7]	Suri C., Jones P., F., Patan S., et al. Requisite role of angiothensin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 1996; 87: 1171-80 (Pub.Med, 8980224).
[8]	Assmus B., Sch?chinger V., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation, 2002; 106: 3009-17 (Pub. Med.: 12473544).
[9]	Britten M.B., Abdolmeali N.D., Assmus B. et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI) mechanistic insights from serial contrast – enhanced magnetic resonance imaging. Circulation, 2003; 108 -: 2012 – 8 (Pub. Med. 14557356).
[10]	Sch?chinger V., Assmus B., Britten M.B., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction – final one-year results of the TOPCARE-AMI trial. J.Am.Coll.Cardiol., 2004;44:1690-9
[11]	Yifn Zhou, Suna Wand Kerth A. Horvath. Direct injection of autologous mesenchymal stromal cells improves myocardial function. Biochem. Biophs, Rec. Sommun., 2009; 18: 390 (3) 902-907.
[12]	Strauer B.E. Brehm M., Zeus T et al. Regeneration of human infracted heart muscle by intracoronary mononuclear bone marrow cell transplantation in humans. Circulation, 2002; 106: 1913-18.
[13]	Perin E.C. Dahmann H.F.R. Borojevic R. et al. Transendocardial autologous bone marrow cell transplantation for severe chronic ischemic heart failure. Circulation, 2003; 107: 2294–302.
[14]	Fuchs S., Satler L.F. Koronovski R. et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease – a feasibility study. J. Am. Coll. Cardiol. 2003; 41:1721-4.
[15]	Lācis A., rglis A. Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiology in the Young, 2011; 21: 110-112.
[16]	Christina L O'Neill , Michelle T O'Doherty , Sarah EJ Wilson , Amer A Rana , Claire E Hirst , Alan W Stitt and Reinhold J Medina. Therapeutic revascularisation of ischemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells. Stem Cell Research & Therapy 2012, 3:31.
[17]	Clabby ML., Canter CE., Moller JH., Bridges ND., Hemodynamic data and survival in children with pulmonary hypertension. J. Am. Coll. Cardiol. 1997; 30: 554-560.
[18]	Zhu JH., Wang XX., Zhang FR., Shang YP et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-Label pilot study. Pediatr. Transplantation 2008; 12: 650-655.
[19]	T. Kinnaird, E. Stabile, M.S. Burnett, C.W. Lee, S. Barr, S. Fuchs, S.E. Epstein. Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms. Circulation Research. 2004; 94: 678-685.
[20]	T. Kinnaird, MBBCh; E. Stabile, MD; M.S. Burnett, PhD; M. Shou, MD; C.W. Lee, MD; S. Barr, MBBCh; S. Fuchs, MD; S.E. Epstein, MDLocal Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms. Circulation. 2004; 109: 1543-1549.
[21]	Gnecehi M, Mirotsu M, Dzun V.J. Stem cell therapy for heart repair. The paracrine paradigm in "Heart regeneration". Max Planck Institute for heart and lung research, Germany. World scientific Publishing, Co. Ptc. Ltd. Copyright@2012. pp 219-245
[22]	Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng. 2004 May-Jun; 10 (5-6): 771-9.

Cite This Article

Plain Text BibTeX RIS

APA Style

Aris Lacis, Inguna Lubaua, Valts Ozolins, Eriks Jekabsons, Andis Lacis, et al. (2013). Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clinical Medicine Research, 2(3), 32-36. https://doi.org/10.11648/j.cmr.20130203.13

Copy | Download

ACS Style

Aris Lacis; Inguna Lubaua; Valts Ozolins; Eriks Jekabsons; Andis Lacis, et al. Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clin. Med. Res. 2013, 2(3), 32-36. doi: 10.11648/j.cmr.20130203.13

Copy | Download

AMA Style

Aris Lacis, Inguna Lubaua, Valts Ozolins, Eriks Jekabsons, Andis Lacis, et al. Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clin Med Res. 2013;2(3):32-36. doi: 10.11648/j.cmr.20130203.13

Copy | Download

@article{10.11648/j.cmr.20130203.13,
  author = {Aris Lacis and Inguna Lubaua and Valts Ozolins and Eriks Jekabsons and Andis Lacis and Mara Ratniece and Andrejs Erglis},
  title = {Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)},
  journal = {Clinical Medicine Research},
  volume = {2},
  number = {3},
  pages = {32-36},
  doi = {10.11648/j.cmr.20130203.13},
  url = {https://doi.org/10.11648/j.cmr.20130203.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20130203.13},
  abstract = {Pulmonary arterial hypertension (APAH, IPAH) is a devastating, progressive disease with increasingly debilitating symptoms [1,2].Intrapulmonary delivery of autologous stem cells could be beneficial for pathogenetic treatment for patients with severe pulmonary arterial hypertension.Two patients with severe pulmonary artery hypertension received intrapulmonary autologous mesenchymal (mononuclear) stem cell transplantation and stem cell transplantation in pulmonary arteries. Patients were examined by scintigraphy of lungs during the periods 12, 14 and 27 months after stem cell transplantation. We find out that perfusion in all lung segments were improved after 14 and 27 months.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)
AU  - Aris Lacis
AU  - Inguna Lubaua
AU  - Valts Ozolins
AU  - Eriks Jekabsons
AU  - Andis Lacis
AU  - Mara Ratniece
AU  - Andrejs Erglis
Y1  - 2013/05/30
PY  - 2013
N1  - https://doi.org/10.11648/j.cmr.20130203.13
DO  - 10.11648/j.cmr.20130203.13
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 32
EP  - 36
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20130203.13
AB  - Pulmonary arterial hypertension (APAH, IPAH) is a devastating, progressive disease with increasingly debilitating symptoms [1,2].Intrapulmonary delivery of autologous stem cells could be beneficial for pathogenetic treatment for patients with severe pulmonary arterial hypertension.Two patients with severe pulmonary artery hypertension received intrapulmonary autologous mesenchymal (mononuclear) stem cell transplantation and stem cell transplantation in pulmonary arteries. Patients were examined by scintigraphy of lungs during the periods 12, 14 and 27 months after stem cell transplantation. We find out that perfusion in all lung segments were improved after 14 and 27 months.
VL  - 2
IS  - 3
ER  -

Copy | Download

Author Information

Aris Lacis

Clinic of Pediatric Cardiology and Cardiac Surgery, University Children Hospital, Riga, Latvia
Inguna Lubaua

Riga Stradins University, Riga, Latvia
Valts Ozolins

Clinic of Pediatric Cardiology and Cardiac Surgery, University Children Hospital, Riga, Latvia
Eriks Jekabsons

Pauls Stradins Clinical University Hospital, Riga, Latvia
Andis Lacis

Riga Stradins University, Riga, Latvia
Mara Ratniece

Pauls Stradins Clinical University Hospital, Riga, Latvia
Andrejs Erglis

Latvian Institute of Cardiology, Riga, Latvia

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Aris Lacis, Inguna Lubaua, Valts Ozolins, Eriks Jekabsons, Andis Lacis, et al. (2013). Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clinical Medicine Research, 2(3), 32-36. https://doi.org/10.11648/j.cmr.20130203.13

Copy | Download

ACS Style

Aris Lacis; Inguna Lubaua; Valts Ozolins; Eriks Jekabsons; Andis Lacis, et al. Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clin. Med. Res. 2013, 2(3), 32-36. doi: 10.11648/j.cmr.20130203.13

Copy | Download

AMA Style

Aris Lacis, Inguna Lubaua, Valts Ozolins, Eriks Jekabsons, Andis Lacis, et al. Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality). Clin Med Res. 2013;2(3):32-36. doi: 10.11648/j.cmr.20130203.13

Copy | Download

@article{10.11648/j.cmr.20130203.13,
  author = {Aris Lacis and Inguna Lubaua and Valts Ozolins and Eriks Jekabsons and Andis Lacis and Mara Ratniece and Andrejs Erglis},
  title = {Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)},
  journal = {Clinical Medicine Research},
  volume = {2},
  number = {3},
  pages = {32-36},
  doi = {10.11648/j.cmr.20130203.13},
  url = {https://doi.org/10.11648/j.cmr.20130203.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20130203.13},
  abstract = {Pulmonary arterial hypertension (APAH, IPAH) is a devastating, progressive disease with increasingly debilitating symptoms [1,2].Intrapulmonary delivery of autologous stem cells could be beneficial for pathogenetic treatment for patients with severe pulmonary arterial hypertension.Two patients with severe pulmonary artery hypertension received intrapulmonary autologous mesenchymal (mononuclear) stem cell transplantation and stem cell transplantation in pulmonary arteries. Patients were examined by scintigraphy of lungs during the periods 12, 14 and 27 months after stem cell transplantation. We find out that perfusion in all lung segments were improved after 14 and 27 months.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - Neo-Revascularization as the Potential Treatment for Patient Suffering from Pulmonary Arterial Hypertension (Myth or Reality)
AU  - Aris Lacis
AU  - Inguna Lubaua
AU  - Valts Ozolins
AU  - Eriks Jekabsons
AU  - Andis Lacis
AU  - Mara Ratniece
AU  - Andrejs Erglis
Y1  - 2013/05/30
PY  - 2013
N1  - https://doi.org/10.11648/j.cmr.20130203.13
DO  - 10.11648/j.cmr.20130203.13
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 32
EP  - 36
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20130203.13
AB  - Pulmonary arterial hypertension (APAH, IPAH) is a devastating, progressive disease with increasingly debilitating symptoms [1,2].Intrapulmonary delivery of autologous stem cells could be beneficial for pathogenetic treatment for patients with severe pulmonary arterial hypertension.Two patients with severe pulmonary artery hypertension received intrapulmonary autologous mesenchymal (mononuclear) stem cell transplantation and stem cell transplantation in pulmonary arteries. Patients were examined by scintigraphy of lungs during the periods 12, 14 and 27 months after stem cell transplantation. We find out that perfusion in all lung segments were improved after 14 and 27 months.
VL  - 2
IS  - 3
ER  -

Copy | Download